Condition: B Cell Lymphoma Intervention: Biological: CD20-directed CAR-T cells Sponsors: Shanghai Tongji Hospital, Tongji University School of Medicine; Cellular Biomedicine Group Ltd. Recruiting
Condition: Refractory B-Cell Lymphoma Intervention: Biological: Anti-CD19 iCAR NK Cells Sponsors: Allife Medical Science and Technology Co., Ltd.; Beijing Cancer Hospital Not yet recruiting
Condition: Refractory B-Cell Lymphoma Intervention: Biological: Anti-CD19/CD22 CAR NK Cells Sponsors: Allife Medical Science and Technology Co., Ltd.; Beijing Cancer Hospital Not yet recruiting
Condition: Refractory B-Cell Lymphoma Intervention: Biological: Anti-CD22 CAR NK Cells Sponsor: Allife Medical Science and Technology Co., Ltd. Not yet recruiting
Condition: Refractory B-Cell Lymphoma Intervention: Biological: Anti-CD19 CAR NK Cells Sponsor: Allife Medical Science and Technology Co., Ltd. Not yet recruiting
Condition: Diffuse Large B Cell Lymphoma Interventions: Drug: Rituximab; Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Cyclophosphamide; Drug: Epirubicin Injectable Product; Drug: Vindesine; Drug: Prednisone Sponsor: The First Affiliated Hospital with Nanjing Medical University Recruiting
Condition: Diffuse Large B-cell Lymphoma Intervention: Biological: CTA101 Sponsors: The First Affiliated Hospital with Nanjing Medical University; Nanjing Bioheng Biotech Co., Ltd. Not yet recruiting
Condition: Diffuse Large B Cell Lymphoma Intervention: Procedure: Biological samples collection Sponsor: The Lymphoma Academic Research Organisation Recruiting
Condition: Diffuse Large B-Cell Lymphoma Interventions: Drug: Ibrutinib; Drug: Rituximab; Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Dexamethasone Sponsors: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea; Janssen-Cilag, S.A. Recruiting
Conditions: Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma Interventions: Drug: Chemotherapy; Procedure: Computed Tomography; Drug: Fludeoxyglucose F-18; Procedure: Positron Emission Tomography Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Indolent B-Cell Lymphomas Intervention: Other: Any treatment, watch and wait policy included Sponsor: Fondazione Italiana Linfomi ONLUS Recruiting
Condition: B Cell Lymphoma Intervention: Drug: Varlilumab Sponsors: University Hospital Southampton NHS Foundation Trust; University Hospital Plymouth NHS Trust; The Christie NHS Foundation Trust; Oxford University Hospitals NHS Trust; Celldex Therapeutics; Cancer Research UK Recruiting
Conditions: Diffuse Large B Cell Lymphoma; Central Nervous System Metastasis Intervention: Sponsors: Herlev Hospital; Weill Medical College of Cornell University Recruiting
Conditions: Diffuse Large B-cell Lymphoma; HIV Intervention: Drug: R-CHOP Sponsors: UNC Lineberger Comprehensive Cancer Center; John E. Fogarty International Center (FIC); National Institutes of Health (NIH); National Cancer Institute (NCI) Recruiting
Conditions: Diffuse Large B-cell Lymphoma (DLBCL); Relapsed Diffuse Large B-cell Lymphoma (DLBCL); Refractory Diffuse Large B-cell Lymphoma (DLBCL) Interventions: Procedure: leukapheresis; Drug: Plerixafor; Drug: carmustine, etoposide, cytarabine, melphalan; Procedure: Autologous Stem Cell Transplantation Sponsors: Memorial Sloan Kettering Cancer Center; Columbia University; NorthShore University HealthSystem; University of Rochester; Medical College of Wisconsin; University of Nebraska; Sanofi; University Hospitals Seidman Cancer Center Recruiting
Condition: Diffuse Large B Cell Lymphoma Intervention: Drug: Ibrutinib and Bortezomib + R-CHOP Sponsors: Prof. Dr. Clemens Schmitt; Charite University, Berlin, Germany; Janssen-Cilag Ltd. Recruiting
Conditions: Diffuse Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma Intervention: Procedure: Molecular Nanotechnology Sponsors: Ohio State University Comprehensive Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Diffuse Large B Cell Lymphoma Interventions: Drug: Blinatumomab; Procedure: Autologous stem cell transplant; Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine; Drug: Melphalan; Procedure: Peripheral blood draws Sponsors: Washington University School of Medicine; Amgen Recruiting
Conditions: Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma Interventions: Drug: Ipilimumab; Drug: Nivolumab Sponsors: Icahn School of Medicine at Mount Sinai; Bristol-Myers Squibb Recruiting
Conditions: Chemotherapy; Diffuse Large B-Cell Lymphoma (DLBCL), Nos; Elderly Interventions: Drug: Rituximab; Drug: Lenalidomide 20 MG; Other: Comprehensive Geriatric Assessment (CGA); Other: Activities of daily living (ADL) scale Sponsors: Centre Hospitalier Universitaire, Amiens; cimiez hospital Nice; Institut Bergonié; groupe hospitalier public sud de l'oise; Henri Mondor University Hospital; Centre Henri Becquerel; Hôpital Charles Foix; Saint-Louis Hospital, Paris, France Not yet recruiting
Conditions: Diffuse Large Cell Lymphoma; Burkitt's Lymphoma; High Grade B-cell Lymphoma Interventions: Drug: Rituximab; Drug: IT Cytarabine Sponsor: New York Medical College Recruiting
Condition: Diffuse Large B Cell Lymphoma Intervention: Drug: Chidamide + R-CHOP regimen Sponsor: First Affiliated Hospital of Zhejiang University Recruiting
Conditions: Diffuse Large B Cell Lymphoma; Relapsed Non Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma Intervention: Drug: azacitidine plus R-GDP Sponsor: Seoul National University Hospital Not yet recruiting
Conditions: Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma; Transformed Lymphoma; Primary Mediastinal Large B Cell Lymphoma Intervention: Biological: BZ019 Sponsors: Institute of Hematology & Blood Diseases Hospital; Shanghai Cell Therapy Engineering Technology Research Center Group Co., Ltd. Recruiting
Condition: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Intervention: Other: 89Zr-atezolizumab PET scans Sponsors: University Medical Center Groningen; VU University Medical Center; Stichting Hemato-Oncologie voor Volwassenen Nederland; Hoffmann-La Roche Recruiting
Condition: Gastric Diffuse Large B-cell Lymphoma Intervention: Drug: Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole Sponsors: National Health Research Institutes, Taiwan; National Taiwan University Hospital; Mackay Memorial Hospital; China Medical University Hospital; Taichung Veterans General Hospital; Changhua Christian Hospital; National Cheng-Kung University Hospital; Chang Gung Memorial Hospital; Kaohsiung Medical University Recruiting
Conditions: Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma Interventions: Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab; Biological: Rituximab Sponsors: University of Washington; National Cancer Institute (NCI) Recruiting
Conditions: Diffuse Large B-Cell Lymphoma; Non Hodgkin's Lymphoma; DLBCL; NHL Interventions: Drug: DA-EPOCH; Biological: Rituximab; Drug: CHOP; Drug: Acalabrutinib Sponsor: National Cancer Institute (NCI) Recruiting
Conditions: Diffuse Large B Cell Lymphoma; Lymphoma Intervention: Drug: Pembrolizumab Sponsors: University of Chicago; Merck Sharp & Dohme Corp. Recruiting
Condition: B-cell Non-Hodgkin Lymphoma Intervention: Biological: CD19-directed CAR-T cells Sponsors: Peking Union Medical College Hospital; Cellular Biomedicine Group Ltd. Not yet recruiting
Conditions: Non-Hodgkin Lymphoma; Lymphoma; Diffuse Large B-Cell Lymphoma; Gray Zone Lymphoma; Primary Central Nervious System Lymphoma Intervention: Biological: Pembrolizumab Sponsor: National Cancer Institute (NCI) Recruiting
Conditions: CD20 Positive; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Stage I Diffuse Large B-Cell Lymphoma; Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma Interventions: Drug: Carboplatin; Drug: Carfilzomib; Drug: Etoposide; Drug: Ifosfamide; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Biological: Rituximab Sponsors: Roswell Park Cancer Institute; National Cancer Institute (NCI); Amgen Recruiting
Conditions: B-cell Non-Hodgkin Lymphoma; Aggressive Interventions: Other: collected at pre-treatment tumor biopsy; Other: Peripheral blood tests; Device: PET/CT Sponsors: Memorial Sloan Kettering Cancer Center; Mayo Clinic; M.D. Anderson Cancer Center; University of Pennsylvania; University of Miami Recruiting
Condition: Recurrent or Refractory B Cell Malignancy Intervention: Biological: Mixed CD19/CD20 CAR-T Transfer Sponsors: Shanghai Longyao Biotechnology Inc., Ltd.; Xuzhou Medical University; Shanghai Jiao Tong University School of Medicine Recruiting
Conditions: Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma Interventions: Drug: TEDD-R; Drug: TEDDI-R; Drug: Ibrutinib; Drug: Cytarabine; Drug: Isavuconazole Sponsor: National Cancer Institute (NCI) Recruiting
Conditions: ALK-Positive Large B-Cell Lymphoma; Atypical Burkitt/Burkitt-Like Lymphoma; Burkitt-Like Lymphoma With 11q Aberration; Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation; Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; EBV-Positive Mucocutaneous Ulcer; High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Human Herpesvirus 8-Positive Neoplastic Cells Present; Intravascular Large B-Cell Lymphoma; Large B-Cell Lymphoma With IRF4 Rearrangement; Plasmablastic Lymphoma; Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type; Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System; Primary Effusion Lymphoma; Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Burkitt Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Lymphomatoid Granulomatosis; Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Burkitt Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Small Intestinal High Grade B-Cell Lymphoma, Not Otherwise Specified; T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Interventions: Biological: Nivolumab; Drug: Varlilumab Sponsor: National Cancer Institute (NCI) Recruiting
Conditions: B-cell Lymphoma; Chronic Lymphocytic Leukaemia; Waldenström Macroglobulinaemia Interventions: Biological: BI-1206 single agent dose escalation phase; Biological: BI-1206 single agent expansion phase; Biological: Combination of BI-1206 with Rituximab Sponsor: Cancer Research UK Recruiting
Conditions: Lymphoma; Leukemia Intervention: Drug: CPI-613 Sponsors: Memorial Sloan Kettering Cancer Center; City of Hope Medical Center; Massachusetts General Hospital; M.D. Anderson Cancer Center; George Washington University Recruiting
Conditions: Diffuse Large B-Cell Lymphoma; Sintilimab; TP53 Mutation Intervention: Drug: Sintilimab-R-CHOP Sponsor: Chinese Academy of Medical Sciences Not yet recruiting
Conditions: Adult Grade III Lymphomatoid Granulomatosis; B-cell Chronic Lymphocytic Leukemia; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Progressive Hairy Cell Leukemia, Initial Treatment; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage 0 Chronic Lymphocytic Leukemia; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma; Testicular Lymphoma; Untreated Hairy Cell Leukemia; Waldenström Macroglobulinemia Interventions: Drug: lenalidomide; Drug: etoposide; Drug: prednisone; Drug: vincristine sulfate; Drug: doxorubicin hydrochloride; Drug: cyclophosphamide; Biological: rituximab; Other: quality-of-life assessment; Other: laboratory biomarker analysis Sponsors: University of Chicago; National Cancer Institute (NCI) Recruiting
Conditions: Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma; Ann Arbor Stage I Grade 1 Follicular Lymphoma; Ann Arbor Stage I Grade 2 Follicular Lymphoma; Ann Arbor Stage I Indolent Adult Non-Hodgkin Lymphoma; Ann Arbor Stage I Mantle Cell Lymphoma; Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma; Ann Arbor Stage II Grade 1 Follicular Lymphoma; Ann Arbor Stage II Grade 2 Follicular Lymphoma; Ann Arbor Stage II Indolent Adult Non-Hodgkin Lymphoma; Ann Arbor Stage II Mantle Cell Lymphoma; Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma; Ann Arbor Stage III Grade 1 Follicular Lymphoma; Ann Arbor Stage III Grade 2 Follicular Lymphoma; Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma; Ann Arbor Stage III Mantle Cell Lymphoma; Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma; Ann Arbor Stage IV Grade 1 Follicular Lymphoma; Ann Arbor Stage IV Grade 2 Follicular Lymphoma; Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma; Ann Arbor Stage IV Mantle Cell Lymphoma; Ocular Adnexal Lymphoma; Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma; Orbit Lymphoma Interventions: Radiation: External Beam Radiation Therapy; Drug: Orbital Radiation Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Diffuse Large B Cell Lymphoma; DLBCL; Cancer Interventions: Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone; Biological: Pegfilgrastim Sponsors: University of Wisconsin, Madison; Medical College of Wisconsin Not yet recruiting
Condition: Lymphoma, Large B-Cell, Diffuse Intervention: Other: Early interim FDG PET/CT after 1 cycle of R-CHOP Sponsor: The Catholic University of Korea Recruiting
Conditions: Diffuse Large B-cell Lymphoma Recurrent; Diffuse Large B Cell Lymphoma Refractory Interventions: Drug: Rituximab; Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Dexamethasone; Drug: Lenalidomide Oral Capsule Sponsor: The First Affiliated Hospital with Nanjing Medical University Recruiting
Conditions: Autologous Hematopoietic Stem Cell Transplantation; Diffuse Large B-cell Lymphoma; Conditioning Interventions: Drug: Busulfan (BU); Drug: Cyclophosphamide (CY); Drug: Etoposide (VP-16) Sponsors: Nanfang Hospital of Southern Medical University; Guangzhou First People's Hospital; Zhujiang Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Third Affiliated Hospital, Sun Yat-Sen University; Peking University People's Hospital Recruiting